Combo Therapy Cuts Relapse Risk in Chronic Inflammatory Demyelinating Polyneuropathy Trial

Treatment with the SC formulation of efgartigimod alfa plus hyaluronidase-qvfc led to a significantly lower risk of relapse in adults with chronic inflammatory demyelinating polyneuropathy.

Related Keywords

,Vyvgart Hytrulo ,Luc Truyen ,Inflammatory Neuropathy Cause ,Inflammatory Rasch Built Overall Disability Scale ,Chief Medical Officer ,